PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc., (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to ...
CELZ-101 (etaroleucel) is designed to induce immune tolerance in complex autoimmune settings, including Type 1 diabetes in the context of pancreatic islet transplantation. The CELZ-101 platform has ...
Creative Medical Technology (NASDAQ:CELZ) shares are trading higher on Wednesday after the company announced one-year follow-up data and significant efficacy using CELZ-001 to treat patients with Type ...
PHOENIX, July 17, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company specializing in regenerative ...
PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a leader in the field of regenerative medicine with a focus on developing novel therapies in immunotherapy, ...
Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative
PHOENIX, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company advancing ...
PHOENIX, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company pioneering ...
-- One-Year Follow-Up Results Confirm Significant Efficacy and No Serious Adverse Effects in Patients Using CELZ-001 for Treating Type 2 Diabetes -- PHOENIX, April 12, 2023 /PRNewswire/ -- Creative ...
PHOENIX - Creative Medical (TASE:PMCN) Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology firm specializing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results